1. Can be undergoing allogenic, or autologous hematopoietic stem cell transplant with source of stem cells being bone marrow, placenta blood or cytokine mobilized peripheral blood; receiving any type of GVHD prophylaxis; patients receiving any type of myeloablative stem cell transplant conditioning regimen (patients receiving non-myeloablative chemotherapy are excluded)
2. Must be between 3 and 25 years old
3. Cannot be receiving oral vancomycin paste or glutamine as an oral supplement
4. Cannot have a known allergy to Echinacea

1. Must have newly diagnosed CNS tumor: anaplastic astrocytoma, glioblastoma multiforme or gliosarcoma, with histological verification of disease
2. Must begin therapy within 31 days of surgery
3. Must have a pre-operative and post-operative brain MRI with and without contrast (requirement for post-operative MRI is waived for patients who undergo biopsy only)
4. Must be 3 years of age or older but less than 22 years of age at time of enrollment
5. Cannot have received any prior treatment other than surgery or corticosteroids
6. Must have adequate bone marrow, kidney, liver and CNS function if seizures are well controlled
7. Must be able to swallow medications
8. Must have performance level of ≥ 50% (Karnofsky) for patients > 16 years of age, and ≥ 50 (Lansky) for patients ≤ 16 years of age
   
   Must have life expectancy eight weeks or greater

1. Must have been diagnosed with any of the following tumors: Ewing sarcoma or peripheral PNET, osteosarcoma, rhabdomyosarcoma, neuroblastoma, high grade astrocytoma and multiforme glioblastoma, low grade astrocytoma, brain stem glioma, ependymoma, hepatoblastoma, malignant germ cell tumors of any site, other rare tumors of interest – soft tissue sarcoma, hepatocellular carcinoma, childhood/adolescent colorectal carcinoma, renal cell carcinoma, adrenocortical carcinoma and nasopharyngeal carcinoma
2. Must have been no greater than 21 years of age inclusive when originally diagnosed with the malignancy
3. Must have measurable disease and histological verification of the malignancy
4. Must have performance level of ≥ 50% (Karnofsky) for patients > 10 years of age, and ≥ 50 (Lansky) for patients ≤ 10 years of age
5. Must have life expectancy of ≥ 8 weeks
6. Must be fully recovered from all acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering the study
7. Must have adequate bone marrow, kidney, liver, and central nervous system (CNS) function
8. Cannot have had prior oxaliplatin exposure or be receiving other anti-cancer agents or another investigational drug
9. Cannot have an uncontrolled infection

1. Patients with a newly diagnosed metastatic Ewing sarcoma family of tumors of bone or soft tissues excluding the central nervous system. Paraspinal tumors of extra-dural origin and Askin’s tumor of the chest wall are eligible.
2. Must be 50 years of age or less at diagnosis; there is no minimum age but patients must have a body surface area (BSA) of at least 0.4 m2
3. Must have performance level Lansky score ≥ 50% for patients less than 17 years of age; patients; 17 years of age or older must have a Karnofsky score ≥ 50%. (Patients whose performance status is adversely affected by a pathological fracture but who are able to undergo treatment will be eligible)
4. Must have no prior history of cancer (including non-melanoma skin cancer) and may not have received chemotherapy, radiation, or a bone marrow/stem cell transplant
5. Must stop taking non-steroidal anti-inflammatory medications, once study treatment has begun
6. Must have adequate kidney, liver, and cardiac function

1. Patients with newly diagnosed embryonal rhabdomyosarcoma, botryoid or spindle cell variants of embryoanl rhabdomyosarcoma or embryonal ectomesenchymoma
2. Must be less than 50 years old at time of enrollment
3. Must have performance status of 0, 1, or 2
4. Cannot have received prior chemotherapy, excluding steroids, or radiation therapy, except for patients transferring from the intermediate risk study
5. Must have adequate kidney function (age dependent), and adequate liver and bone marrow function
6. Must start treatment within 42 days of initial surgical procedure (including biopsy that provided the definitive diagnosis
7. Must have no evidence of uncontrolled infection
8. Must be able to undergo radiation therapy

1. Patients with primary acute myeloid leukemia or myelodysplastic syndrome must have relapsed remission duration of less than one year or have failed to achieve an initial complete response.
2. Patients must have an M2 or M3 bone marrow aspirate at study entry.
3. Patients with acute myeloid leukemia as a secondary cancer are also eligible provided they have had no other therapy for acute myeloid leukemia.
4. Patients may not be older than 21 years of age at the time of entry into the study.
5. Patients must have adequate kidney, liver and cardiac function.

1. Patients must have a confirmed diagnosis of recurrent or refractory Hodgkin’s disease according to study criteria.
2. Patients must be no greater than 30 years of age at the time of enrollment into the study.
3. Patients must have a life expectancy of more than 8 weeks.
4. Patients may have received a minimum of two prior cytotoxic chemotherapy regimens as well as patients who have undergone autologous or allogeneic stem cell transplantation.
5. Patients must have fully recovered form the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy to enter the study.
6. Patients must have adequate bone marrow, kidney, liver, pulmonary and central nervous system function.

1. Patients must have a confirmed diagnosis of neuroblastoma, and categorized as high risk at the time of diagnosis.
2. Patients must not be older than 30 at diagnosis.
3. If patient is enrolled in study A3973, then the patient must have completed front-line therapy followed by ASCT and radiotherapy as outlined in A3973, AND have achieved CR, VGPR or PR at pre-ASCT evaluation.
4. If a patient is not enrolled on the study A3973, the patient will be eligible for this study if they are CR/VGPR/PR after treatment with one of the study designated induction regimens prior to a single cycle of high-dose therapy and ASCT.
5. No later than 9 months from the date of starting the first induction chemotherapy after diagnosis to the date of autologous stem cell transplantation should elapse.
6. Patients must not have progressive disease or biopsy proven residual disease if not enrolled on the study A3973 at the time of enrollment in this study.
7. Patients must have adequate renal, liver, cardiac, pulmonary and central nervous function.

1. Biopsy proven rhabdomyosarcoma, undifferentiated sarcoma or ectomesenchymoma at first relapse or first occurrence of disease progression.
2. Patients who have undergone prior stem cell transplant are not eligible.
3. Patients must have adequate bone marrow, kidney, liver, heart and neurologic function.
4. Must have a performance status of 50-100.
5. Must not have disease impinging on or within the brain or spinal cord.
6. Must not have a history of ischemic heart disease.
7. Age less than 21 years of age at time of initial diagnosis of rhabdomyosarcoma, undifferentiated sarcoma or ectomesenchymoma

1. Patients with newly diagnosed CD30+ anaplastic large cell lymphoma, Murphy Stage III and IV. Patients who have received limited dose radiation therapy or steroids for management of a mediastinal mass will still be eligible for randomization.
2. Patients with disease limited to the skin or B-cell large cell lymphoma are not eligible. 
3. Patients must have adequate liver and heart function.
4. Performance status will not be used to exclude any patients.
5. Patients must be less than 21 years of age.

1. Must have biopsy proven desmoid tumor at first presentation or any recurrence. Patients with newly diagnosed desmoid tumor are eligible if (a) they have had no prior therapy and (b) they have disease for which complete surgical resection and/or radiation therapy is not feasible. After attempted surgical resection, patients are only eligible if there is gross residual disease than can be measured on MRI scan. Patients with recurrent desmoid tumor are eligible if (a) they have radiographically documented recurrent or progressive disease, (b) prior anti-tumor therapy has not included treatment with non-steroidal anti-inflammatory drugs or estrogen antagonists, and (c) they have had no chemotherapy or radiation therapy for the present recurrence.
2. Must have measurable disease.
3. Patients must have adequate bone marrow, kidney, liver and heart function.
4. Must have a Lansky/Karnofsky performance status of 50-100.
5. Must not have a history of peptic ulcer disease, significant gastrointestinal hemorrhage, deep vein thrombosis, aspirin allergy, diagnosis of hemophilia, von Willebrand’s disease or other clinically significant bleeding diathesis.
6. Must be no greater than 18 years of age.

1. Primary extracranial germ cell tumors, which are histologically verified to be yolk sac tumor, embryonal carcinoma, choriocarcinoma or teratoma with malignant elements are eligible. 
2. Stage I-IV malignant testicular germ cell tumors or Stage I-III malignant ovarian germ cell tumors or Stage I-II malignant extragonadal germ cell tumors.
3. No previous chemotherapy or radiation therapy.
4. Patients must be 21 years of age or less at diagnosis, except patients with testicular primary tumors, who must be less than 15 years of age.

1. Patients must have Hodgkin’s disease which has relapsed or become refractory to conventional therapy. Stage IA/IIA patients with nodal disease previously treated with radiation only or less than 3 courses of standard dose chemotherapy are not eligible. Measurable disease is not required. 
2. Should be enrolled concurrently on the current COG salvage chemotherapy trial for recurrent/refractory Hodgkin’s disease. For patients ineligible for a COG salvage chemotherapy trial, salvage induction chemotherapy with ifosfamide and vinorelbine is recommended. Patients who have been treated on other appropriate salvage therapy may be enrolled only with the permission of the Study Chair.
3. Patients must have adequate bone marrow, kidney, liver, lung and heart function.
4. Must have a Lansky/Karnofsky performance status of 50-100.
5. Must be less than 30 years of age

1. Patients must be > 3 years and < 22 years at the time of enrollment.
2. Patients must have a newly diagnosed CNS tumor as: anaplastic astrocytoma, glioblastoma multiforme or gliosarcoma. Patients with diffuse intrinsic pontine glioma or spinal cord malignant glioma are eligible. Patients with evidence of neuraxis dissemination by spinal MRI or metastatic disease are not eligible.
3. Must be newly diagnosed and previously untreated for current diagnosis.
4. Patients must have adequate bone marrow, kidney, liver and neurologic function.
5. Must have a Lansky/Karnofsky performance status of 50-100.

1. Patients must have recurrent or refractory CD20+ NHL or B-cell ALL. CD20 positivity must be confirmed by either flow cytometry of tumor tissue or involved marrow or by CD20 immunostaining.
2. Patients must have measurable disease, documented by clinical, radiographic, or histologic criteria, and be in first or later recurrence or have disease that is primary refractory to conventional therapy.
3. Patients must have a life expectancy of greater than or equal to 2 months.
4. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
5. Patients must have normal bone marrow, liver and kidney function.

1. Patients with newly diagnosed, pathologically confirmed Hodgkin disease (all histologies) are eligible for this protocol.
2. Patients must have stage IB, IIB, IA (with bulk disease), Stage IIA (with bulk disease), stage IIAE, Stage IIIA, IIIAE, IIIAS, IIIAE+S or stage IVA disease.
3. Patients may not have received any previous chemotherapy or radiation therapy.
4. Patients must have normal kidney, liver, heart and lung function.

1. All children with newly diagnosed, previously untreated JMML will be eligible for this treatment protocol.
2. Patients must have adequate liver and kidney function.

1. Biological specimens, defined as malignant or benign tumor-related cells/tissue including solid tumors and leukemia, must be available for submission.
2. Pathology review specimens must be available for submission for central review and include nasopharyngeal carcinoma, thyroid carcinoma, melanoma and dysplastic nevi (atypical moles), adrenocortical carcinoma, colorectal carcinoma, pleuropulmonary blastoma, embryonal undifferentiated sarcoma of the liver, other rare tumors as defined by a participating COG institution.
3. Patients must not be eligible for a disease-specific biology/banking protocol. 
4. Patients are eligible t the time of diagnosis of their primary neoplasm (benign tumor-related or malignant), or at the time of second look surgery, or at the development of a second malignant neoplasm.

1. Patients must have a Ph+ chronic phase CML and most have either recurred after stem cell transplant or subsequent chronic phase; newly diagnosed CML in first chronic phase with no prior chemotherapy other than hydroxyurea.
2. Patients must have a life expectancy of greater than or equal to 8 weeks.
3. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
4. At least 3 months must have elapsed since stem cell transplant or craniospinal XRT.
5. At least 2 weeks must have elapsed since local palliative XRT and at least 6 weeks must have elapsed if other substantial BM radiation.
6. Patients must have adequate kidney, liver and CNS function.

1. Patients must have newly diagnosed acute leukemia with at least 25 percent blasts in the bone marrow or peripheral blood with 50 percent blasts if bone marrow aspiration is not performed.
2. Patient may have suspended acute Lymphoblastic leukemia.

1. Patients must be eligible for an enrolled on AALL03B1.
2. Patients must have newly diagnosed B-precursor ALL.
3. Patients must have had no prior cytotoxic chemotherapy with the exception of steroids and intrathecal cytarabine.
4. Patients must be enrolled on the study before systemic treatment begins. The only exceptions to this include previous treatment with corticosteroids.

1. Patients must have histologically confirmed Ewing Tumor (Ewing’s sarcoma or peripheral PNET) or bone or soft tissue.
2. Patients must not have received prior chemotherapy.
3. Patients must be registered at diagnosis.
4. Patients must have normal cardiac, and liver function.

1. Patients must have an institutional diagnosis of rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS, including aggressive fibromatosis, Desmoplastic round cell tumors, and malignant rhabdoid tumors) or other soft tissue neoplasms established by pathologic examination of tissue or bone marrow and must have pathologic specimens of tumor-containing tissue or bone marrow beyond that needed by the institution for rendering the diagnosis.
2. Patients with Ewing sarcoma/PNET or osteogenic sarcoma are not eligible for this protocol.

1. Patients must have newly diagnosed Neuroblastoma seen at COG institutions.
2. Patients must be registered within 2 weeks following diagnosis and every effort should be made to register patients within 1 week of diagnosis.
3. Patients with relapsed Neuroblastoma who were not enrolled on ANBL00B1 at diagnosis are not eligible.

1. All patients with either newly diagnosed or recurrent Ewing Sarcoma are eligible.
2. Patients are not required to enter a therapeutic study to register to this study.
3. Patients should be registered within two weeks of diagnosis.

1. Newly diagnosed lymphoblastic lymphoma.
2. Less than 25% tumor cells in the bone marrow.
3. Patients must be at least 12 months old and less than 22 years old at study entry.
4. Adequate heart function. 
5. Patients must not have received prior chemotherapy. Intrathecal cytarabine is allowed if administered within 72 hours of starting protocol therapy.

1. Patients must have biopsy proven
2. hepatoblastoma and must be registered not more than 28 days from initial surgical procedure.
3. Patients must not have received prior therapy (except tumor resection).
4. Patients with hepatocellular carcinoma are not eligible.
   Patients must have normal renal function.

1. Children > 1 month and < 21 years 
2. Previously untreated morphologically diagnosed myeloid leukemia except FAB M3. Patients with granulocytic sarcoma, documented preleukemia (myelodysplastic syndrome), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia, refractory anemia, refractory anemia with ringed sideroblasts, and mixed lineage leukemia are eligible. 
3. No prior chemotherapy or radiation therapy.

• Patients treated for brain tumor at a COG institution.
• Brain tumor biological specimens, derived from primary tumors of the central nervous system, must be available for submission.

1. Age < 21 years.
2. Non-metastatic alveolar rhabdomyosarcoma, undifferentiated sarcoma or ectomesenchymoma.
3. Stages 2 and 3, Clinical Group III embryonal rhabdomyosarcoma and ectomesenchymoma with embryonal features.
4. Patients < 10 years of age with Stage 4, Clinical Group IV embryonal rhabdomyosarcoma and ectomesenchymomas with embryonal features.
5. No prior chemotherapy.
6. Adequate renal and liver function.

1. Progressive disease following surgical excision based on clear radiological or clinical evidence of progression, or an incomplete excision with necessity to begin treatment because of a risk of neurologic impairment with progression. All patients on study must have residual tumor.
2. Astrocytoma or other eligible tumors (oligodendroglial, mixed gliomas, neuronal, chiasmatic-hypothalamic tumor without histologic confirmation) interpreted as low grade (WHO grades I and II).
3. Age less than 10 years.
4. Intrinsic brainstem tumors of the pons or intrinsic to the optic nerve within the orbit without intracranial extension and involvement of the optic chiasm are not eligible.
5. Children with clinically or radiographically progressive tumors must be enrolled and randomized within six weeks of clear radiological or clinical evidence or progression. Children with newly diagnosed incompletely resected tumors who are considered to require immediate therapy must be enrolled within six weeks of surgery.
6. No prior therapy except diuretics, corticosteroids and surgery.
7. Adequate renal function.

1. Must have histologic verification of PNET at diagnosis. Patients with one of the following diagnoses will be eligible: primitive neuroectodermal tumor, atypical teratoid/rhabdoid tumor, medulloblastoma, desmoplastic medulloblastoma, ependymoblastoma, medullomyoblastoma, spongioblastoma, spongioblastoma polare, spongioblastoma - primitive polar, medulloepithelioma, neuroblastoma NOS, pineoblastoma.

2. Age > 3 years and less than 22 years at time of diagnosis

3. No prior chemotherapy or radiotherapy

4. Adequate bone marrow, kidney, and liver function

5. Must begin treatment within 31 days of definitive surgery

Kay Krimmel 216-844-3999

1. Patients with newly diagnosed, pathologically confirmed Hodgkin’s disease are eligible.

2. Patients ages 0 – 21 years are eligible.

3. Patients must have adequate renal, hepatic, cardiac and pulmonary function.

4. Patients may not have received any previous chemotherapy or radiation therapy.

Kay Krimmel 216-844-3999

1. Patients must have a diagnosis of ALL and must fall into one of the following 4 subgroups: 1) Ph+ ALL; 2) hypodiploid patients with greater than or equal to 44 chromosomes; 3) patients who had an M3 (less than 25% blasts)